Inolex announced today that it is listing the company’s 6.2-acre property located at 2101 South Swanson Street in Philadelphia, PA for sale on the commercial real estate market.
The site sale marks a continuation of the company’s long-term growth strategy as a provider of natural, sustainable, and innovative ingredients for health, beauty, and wellness.
In 2019, Inolex set in motion the successful transition of its US production platform to a new flagship manufacturing facility in Charlotte, North Carolina, US.
With steady operations in Charlotte and a unified global team, the company is well positioned to continue its long-term growth momentum.
“Establishing robust manufacturing capabilities in Charlotte was a generational move to anticipate and serve global demand,” said David Plimpton, CEO and President of Inolex.
“Likewise, the divestiture of the Philadelphia site is the next important step in our long-term growth plans that reflects our entrepreneurial, innovative spirit as a company.”
Inolex intends to maintain a strong presence in the greater Philadelphia region to continue to serve its customers and partners. Concurrent to the site sale, the company is evaluating options for new offices and laboratory space in the greater Philadelphia region.
“Since inception, Inolex has been a company that has adapted and evolved to remain relevant in the market. We now have an opportunity to deploy our deep technical expertise as both a designer and a manufacturer of ingredients with space, equipment, and means for innovation that will serve us and our customers for years to come,” said Plimpton.
